Praxis Precision Medicines Inc Asset Resilience Ratio
Praxis Precision Medicines Inc asset resilience ratio. Praxis Precision Medicines Inc (PRAX) has an Asset Resilience Ratio of 20.42% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PRAX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Praxis Precision Medicines Inc (2020–2025)
Asset resilience ratio of Praxis Precision Medicines Inc from 2020 to 2025. This chart shows how Praxis Precision Medicines Inc's Asset Resilience Ratio has changed over time. See PRAX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Praxis Precision Medicines Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Praxis Precision Medicines Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $283.79 Million | 20.42% |
| Total Liquid Assets | $283.79 Million | 20.42% |
Asset Resilience Insights
- Good Liquidity Position: Praxis Precision Medicines Inc maintains a healthy 20.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Praxis Precision Medicines Inc Industry Peers by Asset Resilience Ratio
Compare Praxis Precision Medicines Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Praxis Precision Medicines Inc Asset Resilience Ratio by Year (2020–2025)
Praxis Precision Medicines Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Praxis Precision Medicines Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.80% | $242.00 Million | $937.91 Million | -10.88pp |
| 2024-12-31 | 36.68% | $177.19 Million | $483.11 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $87.95 Million | -- |
| 2022-12-31 | 33.77% | $38.87 Million | $115.13 Million | -13.10pp |
| 2021-12-31 | 46.87% | $137.21 Million | $292.75 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $303.18 Million | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more